RWLK REWALK ROBOTICS LTD

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ReWalk Robotics Ltd. of a Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of ReWalk Robotics Ltd. (“ReWalk”) (NASDAQGM:RWLK) pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014.

You are hereby notified that a securities class action lawsuit has been commenced in the Superior Court of the State of California, County of San Mateo. If you purchased or otherwise acquired ReWalk securities pursuant to the initial public offering your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/rewalk-robotics-rwlk

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that while the Registration Statement filed pursuant to the IPO stated that the U.S. Food and Drug Administration had classified ReWalk as subject to special controls, including compliance with medical device consensus standards, performance of a postmarket surveillance clinical study demonstrating a reasonable assurance of safety and effectiveness in urban terrain, and a training program, among other things, the Company failed to disclose that it was unable to comply with the special controls. ReWalk also omitted that it had received a Warning Letter from the FDA in September of 2015, in which the FDA outlined ReWalk’s failures to propose and commence an adequate postmarket surveillance plan. On May 10, 2016, ReWalk revealed that at the time of the IPO, the company had been unable to comply with the FDA's special controls due to inadequate staffing.

If you suffered a loss in ReWalk and would like to obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/rewalk-robotics-rwlk.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
05/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

 PRESS RELEASE

Lifeward Expands International Distribution of its ReWalk® Personal Ro...

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable...

 PRESS RELEASE

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic...

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for  of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBORO...

 PRESS RELEASE

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Ap...

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received it...

 PRESS RELEASE

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Lifeward Ltd. Reports Third Quarter 2025 Financial Results Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch